Related Experiment Video
Updated: Mar 15, 2026
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a
Jiayu Zhu1, Hua Wang2,3,4, Cheng-Cheng Liu5,6
1Department of Obstetrics and Gynecology, Nanfang Hospital of Southern Medical University, Guangzhou, 510515, Guangdong, People's Republic of China.
Purpose:
The Glasgow Prognostic Score (GPS), an inflammation-based prognostic score systems composed of C-reactive protein and albumin, has been reported to be predictive of survival in several types of malignancies. The prognostic significance of GPS in epithelial ovarian cancer (EOC) remains unclear. We conducted this study to assess the prognostic value of GPS in a cohort of patients with advanced EOC receiving neoadjuvant chemotherapy (NAC) followed by debulking surgery.
Methods:
Six hundred and seventy-two patients newly diagnosed with advanced EOC were retrospectively analyzed.
Results:
High GPS was significantly related to Eastern Cooperative Group performance status, histological type, histological grade and the size of residual tumor after the debulking surgery. In addition, patients with higher GPS at diagnosis achieved lower complete remission rates after NAC (P < 0.05) and had shorter progression-free survival (PFS; P < 0.001) and overall survival (OS; P < 0.001). Multivariate analysis showed high GPS was independent adverse predictors of PFS and OS.
Conclusions:
Our data demonstrated that GPS at diagnosis is a powerful independent prognostic factor for advanced epithelial ovarian cancer. However, further studies are needed to prospectively validate this prognostic model and investigate the mechanisms underlying the correlation between high GPS and poor prognosis in advanced epithelial ovarian cancer.
